286 related articles for article (PubMed ID: 20047147)
1. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
2. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
Kalgutkar AS; Obach RS; Maurer TS
Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Fontana E; Dansette PM; Poli SM
Curr Drug Metab; 2005 Oct; 6(5):413-54. PubMed ID: 16248836
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.
Yadav J; Paragas E; Korzekwa K; Nagar S
Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452
[TBL] [Abstract][Full Text] [Related]
6. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
Kamel A; Harriman S
Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation.
Zhang T; Rao J; Li W; Wang K; Qiu F
Drug Metab Rev; 2020 Nov; 52(4):501-530. PubMed ID: 33043714
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
10. Application of mechanism-based CYP inhibition for predicting drug-drug interactions.
Zhou ZW; Zhou SF
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):579-605. PubMed ID: 19466877
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
12. Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Pelkonen O; Mäenpää J; Taavitsainen P; Rautio A; Raunio H
Xenobiotica; 1998 Dec; 28(12):1203-53. PubMed ID: 9890159
[No Abstract] [Full Text] [Related]
13. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
14. Enzyme kinetics for clinically relevant CYP inhibition.
Zhang ZY; Wong YN
Curr Drug Metab; 2005 Jun; 6(3):241-57. PubMed ID: 15975042
[TBL] [Abstract][Full Text] [Related]
15. The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.
Mikov M; Đanić M; Pavlović N; Stanimirov B; Goločorbin-Kon S; Stankov K; Al-Salami H
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):881-890. PubMed ID: 28534261
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes.
Kanayama N; Kanari C; Masuda Y; Ohmori S; Ooie T
Xenobiotica; 2007 Feb; 37(2):139-54. PubMed ID: 17484517
[TBL] [Abstract][Full Text] [Related]
17. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.
Isoherranen N; Hachad H; Yeung CK; Levy RH
Chem Res Toxicol; 2009 Feb; 22(2):294-8. PubMed ID: 19216580
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
19. Computational prediction of cytochrome P450 inhibition and induction.
Kato H
Drug Metab Pharmacokinet; 2020 Feb; 35(1):30-44. PubMed ID: 31902468
[TBL] [Abstract][Full Text] [Related]
20. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Brandon EF; Meijerman I; Klijn JS; den Arend D; Sparidans RW; Lázaro LL; Beijnen JH; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):935-43. PubMed ID: 16162970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
